TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic (diagnosis of hepatitis C more than or 6 months before the screening period) HCV infection. Geno- and subtype should be determined or confirmed at screening, and should be 1a or 1b~* Never received (Peg) IFN, RBV or any other approved or investigational antiviral treatment for chronic HCV infection~* HCV RNA level of \>100,000 IU/mL at screening (as assessed by standard quantitative in vitro nucleic acid amplification assay)~* Patients having good accessible veins~Exclusion Criteria:~* Evidence of liver cirrhosis or decompensated liver disease~* Patient coinfected with HIV-1 or HIV-2, or hepatitis A or B virus infection, or active tuberculosis at study screening~* Patient infected/coinfected with non-genotype-1 HCV at study screening~* Patient with any cardiac disease at screening, or any active clinically significant disease, or medical history or physical examination findings during screening~* Patient having uncontrolled/unstable disease such as diabetes, epilepsy, a manifest psychiatric disease, thyroid disease or disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Panel I (Type: EXPERIMENTAL): Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
- Panel II (Type: EXPERIMENTAL): Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
- Panel III (Type: EXPERIMENTAL): Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
- Panel IV (Type: EXPERIMENTAL): Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Developing a Non-invasive Cardiac Functional Health Status Measurement Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heart failure patient eligibility shall consist of the following:~Group 1a: 5 adult heart transplant patients~* Age ≥ 21 years old and \<74 years old~* Speaks and understands English~* Provides Informed Consent~Group 1b: 5 pediatric heart transplant patients~* Age ≥ 7 years old and \< 21 years old~* Speaks and understands English~* Provides Informed Consent~Group 2: 5 adult heart failure patients~* Age ≥ 21 years old and \<74 years old~* Speaks and understands English~* Provides Informed Consent~Group 3: 5 adult aged Fontan patients~* Age ≥ 21 years old and \<74 years old~* Speaks and understands English~* Provides Informed Consent~Group 4: 5 pediatric Fontan patients~* Age ≥ 7 years old and \< 21 years old~* Speaks and understands English~* Provides Informed Consent~Group 5: 5 pediatric patients limited to heart murmurs~* Age ≥ 7 years old and \< 21 years old~* Speaks and understands English~* Provides Informed Consent~Group 6: 5 normal adult patients~* Age ≥ 21 years old and \<74 years old~* Speaks and understands English~* Provides Informed Consent~Exclusion Criteria:~* • Unstable patients per judgment of the clinician prior to the start of the treatment~  * Patients unable to have blood pressure cuff measured on the upper arm~ * Inability to wear monitor on forehead~ * Patients will be excluded from the study if they have eaten, consume caffeinated beverages, or taken hypertensive medications within 2 hours of testing

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- CVInsight (TM) (Type: EXPERIMENTAL): Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Feasibility Study of Mindfulness-Oriented Recovery Enhancement With Pregnant Women With Opioid Use Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be pregnant.~* Must be able to communicate in English.~* Must have met criteria for opioid use disorder in the past year.~Exclusion Criteria:~* None.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Mindfulness-Oriented Recovery Enhancement via tele-health (Type: EXPERIMENTAL): Participants will be assigned to 8 weeks of Mindfulness-Oriented Recovery Enhancement delivered via tele-health.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female age \< 36 years~* FSH \< 12 IU/l~* BMI 18-29 kg/m2~* Regular cycle (25-35 days)~* No major uterine or ovarian abnormalities~* No previous IVF cycles~* Written informed consent~Exclusion Criteria:~* Oocyte donation~* Medical contra indication for pregnancy or IVF treatment~* Endometriosis ≥ grade 3~* Polycystic Ovarium Syndrome (PCOS)~* Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: t

Study Arms:
- Start rFSH cycle day 2 (Type: EXPERIMENTAL): None
- Start rFSH on cycle day 5 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation (NEURAPAS Balance)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Depressive symptoms of mild intensity, as defined in the International Classification of Mental Disorders (ICD 10), codes F32.0 (mild depressive episode) and F33.0 (recurrent depressive disorder, current episode mild)~* SDS Index between 51 and 59 (this criterion was declared null and void on 21.02.02 in the 2nd Amendment)~* HAM-D21 scores between 10 and 17~* Between 18 and 70 years of age~* Duration of depression: not less than 4 weeks and not longer than 2 years~* Signed informed consent to take part in the clinical study after verbal and written information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Verum (Type: EXPERIMENTAL): Neurapas balance, film-coated tablet
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Post-Traumatic Brain Injury (Post-TBI) Fatigue and Its Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Individuals who sustained a TBI with a documented loss of consciousness or evidence of a TBI on neuroimaging studies and who are at least 12 months post-injury, who complain of fatigue and who have scores of 22 or above on the Barroso Fatigue Scale will be eligible to participate in this study. Subjects must not meet criteria for alcohol or substance abuse using the Structured Clinical Interview for DSM-IV (SCID) for at least six months prior to study enrollment.~Exclusion Criteria:~- Diagnosis of chronic neurological disease (including Lyme disease), narcolepsy, current infectious disease, chronic fatigue syndrome, fibromyalgia, anemia, hypothyroidism not adequately controlled with medication, blood pressure greater 150/100 mm Hg, or clinically significant major systemic disease. In addition, individuals taking medications which are known to cause fatigue will be excluded from participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modafinil (Type: EXPERIMENTAL): single dose of 200 mg. a day of modafinil for four weeks
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed DCIS by breast core biopsy with a corresponding lesion on breast MRI of at least 1-cm3 in volume.~* Patients may have undergone treatment with prior chemotherapy if this was greater than 12 months prior to current diagnosis.~* Age \>18 years.~* ECOG performance status \<2 (Karnofsky \>60%)~* Life expectancy of greater than 12 months.~* Normal organ and marrow function as defined below:~* leukocytes \>3,000/mcL~* absolute neutrophil count \>1,500/mcL~* platelets \>100,000/mcL~* total bilirubin within normal institutional limits~* AST(SGOT) \& ALT(SGPT)within normal institutional limits~* creatinine \<1.5 times institutional upper limit of normal or creatinine clearance \>60 mL/min/1.73 m2~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Pregnancy~* Patients who have undergone prior excisional biopsy for DCIS.~* Patients who are unable to undergo MRI due to claustrophobia or other reason.~* Patients with ipsilateral treatment for DCIS or breast cancer within 12 months prior to entering this study.~* Patients receiving any other chemotherapy or investigational agents.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extracts or sensitivity to green tea.~* Uncontrolled concurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women with Ductal Carcinoma in Situ (Type: EXPERIMENTAL): Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, Richter's transformation or T-PLL who have previously been treated with fludarabine or another regime are eligible.~2. Patients with histologically or cytologically confirmed Richter's transformation.~3. Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) less than x 2 normal levels.~4. Women of childbearing potential who have a negative pregnancy test prior to azacytidine treatment.~5. Women of childbearing potential who agreed not to become pregnant and men agreed not to father a child while on azacytidine treatment.~6. Performance 0-2 (ECOG). Adequate liver function (bilirubin of less than2mg/dl) and renal function (creatinine less than 2mg/dl). Adequate cardiac functions (NYHA cardiac III-IV excluded).~7. Signed informed consent.~Exclusion Criteria:~1. Breast feeding or pregnant females. Patients of (male and female) childbearing potential should practice effective methods of contraception; otherwise, they will be excluded. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~2. Known or suspected hypersensitivity to azacytidine or Mannitol.~3. Active and uncontrolled infections.~4. Patients with advanced malignant hepatic tumors.~5. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-Azacytidine (Type: EXPERIMENTAL): 5-Azacytidine 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to comprehend and willing to sign an ICF and willing to comply with all study procedures and restrictions for the duration specified in the Schedule of Activities. If non-written consent is given, a Legal Designee of the patient must sign the ICF form.~* Completed dosing in CY 5031~Exclusion Criteria:~* Has taken investigational study drug (other than reldesemtiv) prior to dosing, within 30 days or five half-lives of the prior agent, whichever is greater~* Presence on Day 1 of any medically significant cardiac, pulmonary, gastrointestinal, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data.~* Use of a strong cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to first dose of reldesemtiv in CY 5032 or a strong CYP3A4 inducer within 14 days prior to first dose of reldesemtiv in CY 5032~* Use of a medication that is an OCT1/OCT2 substrate within 7 days prior to first dose of reldesemtiv in CY 5032~* Currently participating in another trial, managed access program, open label extension, early access program, or through the right to try act is receiving an investigational drug or received an investigational drug or device within 30 days (or 5 half-lives for drugs, whichever is longer) prior to Day 1. Patients also cannot be taking outside of a clinical trial certain investigational drugs (which includes drugs, supplements, and nutraceuticals) that are currently being studied or have been studied for the treatment of ALS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reldesemtiv 300 mg twice daily (Type: EXPERIMENTAL): Patients in this arm take 1 reldesemtiv 300 mg oral tablet twice a day for a 600 mg total daily dose (TDD). Participants who had been down titrated during the parent trail take 150 mg by mouth twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patients must have a diagnosis of inoperable hepatocellular carcinoma.~* The patients who have an AFP level higher than 400 ng/ml and an appearance characteristic of cancer of the liver do not need histological confirmation. These patients must however have a negative serology for the antigen of surface of hepatitis B If serology for this antigen is positive, they must have a rate of AFP higher than 4000 ng/ml.~* Presence of one or more lesions measurable(s) according to criteria's RECIST.~Exclusion Criteria:~* Other anti-cancer treatments are not authorized during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent prior to initiation of any study mandated procedure~2. Male or female ≥ 40 and ≤ 75 years of age~3. Women of childbearing potential1 must use a reliable method of contraception~4. Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on pulmonary function tests~5. Current or past smokers of ≥ 10 pack years~6. Ability to perform exercise testing without supplemental oxygen (in the best opinion of the investigator)~7. Confirmed pulmonary hypertension by right heart catheterization (RHC)~Exclusion Criteria:~1. Other causes of pulmonary hypertension than COPD~2. BMI \> 35 kg/m2~3. Conditions considered as contraindications for cardiopulmonary exercise testing (CPET) and/or inability to pedal on a cycle ergometer~4. Pregnant or nursing~5. Currently (within 30 days prior to RHC) taking specific pulmonary arterial hypertension (PAH) therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil, epoprostenol, treprostinil, iloprost, beraprost)~6. Participation in any other clinical trial, except observational, or receipt of an investigational product within 30 days prior to RHC visit~7. Known concomitant life-threatening disease with a life expectancy \< 12 months~8. Known hypersensitivity to iloprost or any of the excipients of the drug formulations

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- iloprost (Type: EXPERIMENTAL): single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
- placebo (Type: PLACEBO_COMPARATOR): matching placebo using the power disc-6 with I-neb AAD system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Function in Patients Submitted to Myocardial Revascularization Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* both sexes,~* aged from 18 to 75 years,~* submitted to revascularization surgery of the myocardium~* extracorporeal circulation,~* who had consented to participation by signing the Terms of Free and Clear Consent.~Exclusion Criteria:~* history of hepatic or renal dysfunction,~* history involving acute myocardial infarct~* patients that made use of vitamin C and E;~* patients presenting other cardiac pathologies (valvular, congenital, corrected or not in the same operational act).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 Isoflurane (Type: None): The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
- 2 Propofol (Type: None): The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues